Trial Profile

A Long-term Open-label Extension Study to Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 07 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Batoclimab (Primary)
Indications Myasthenia gravis
Focus Adverse reactions
Sponsors Harbour BioMed

Most Recent Events

30 Apr 2024 According to HanAll Biopharma media release, topline data from this study anticipated in the second half of 2024
28 Mar 2024 Status changed from recruiting to active, no longer recruiting in Mar 2023, according to Harbour Biomed media release.
06 Mar 2023 Planned primary completion date changed from 30 May 2023 to 30 Sep 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com